Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

210
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
210
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

212
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
212
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

339
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
339
The Ras Gene02:38

The Ras Gene

6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.3K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

197
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
197

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tyrosine Stickers Regulate Phase Separation and Hierarchical Assembly of Silk Fibroin Nanoclusters.

ACS nano·2026
Same author

Functional Pulmonary Atresia With Overlapping Dilated, Hypertrophic, and Excessive Trabeculation Cardiomyopathy in a Neonate With a TPM1 Mutation.

CJC pediatric and congenital heart disease·2026
Same author

Education Research: Defining Competencies and Consensus in Canadian Epilepsy Fellowship Training: A Thematic Discourse Analysis of Expert Perspectives.

Neurology. Education·2026
Same author

Mapping neuro-vascular unit communications reveals distinct angiogenic programs across developing mouse brain regions.

Nature communications·2026
Same author

Attenuation of epicardial activation and myofibroblast abundance via the Fbln2-Nupr1b axis stimulates cardiac regeneration in zebrafish.

Nature cardiovascular research·2026
Same author

Parent-to-parent recommendations for coping with congenital heart disease: a mixed-methods study.

Archives of disease in childhood·2026

Related Experiment Video

Updated: Jul 16, 2025

Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note
05:54

Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note

Published on: June 13, 2016

17.3K

Treatment of Refractory Epilepsy With MEK Inhibitor in Patients With RASopathy.

Gianluca D'Onofrio1, Marie-Ange Delrue2, Anne Lortie3

  • 1Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy; Division of Pediatric Neurology, Department of Neurosciences, CHU Sainte-Justine, Montreal, QC, Canada.

Pediatric Neurology
|September 18, 2023
PubMed
Summary

Trametinib, a MEK inhibitor, shows promise for treating drug-resistant epilepsy in RASopathies. One patient achieved sustained seizure freedom, while another experienced temporary benefit and a rebound effect upon discontinuation.

Keywords:
EpilepsyMEK inhibitorsRASopathiesTargeted therapyTrametinib

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.1K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.7K

Related Experiment Videos

Last Updated: Jul 16, 2025

Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note
05:54

Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note

Published on: June 13, 2016

17.3K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.1K
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.7K

Area of Science:

  • Neurology
  • Genetics
  • Pharmacology

Background:

  • RASopathies spectrum syndromes increase epilepsy risk, often leading to refractory epileptic encephalopathy.
  • Current management for these conditions is primarily symptomatic.

Purpose of the Study:

  • To evaluate trametinib, a MEK1-2 inhibitor, as a precision medicine strategy for drug-resistant epilepsy in patients with RASopathies.

Main Methods:

  • Two patients with RASopathies (cardiofaciocutaneous and Schimmelpenning syndromes) received trametinib (0.025 mg/kg/day).
  • Patient 1: BRAF mutation; Patient 2: KRAS mutation.

Main Results:

  • Patient 1 experienced significant EEG improvement and became seizure-free for over six months.
  • Patient 2 showed initial seizure freedom, followed by recurrence and a rebound effect after trametinib discontinuation due to colitis.

Conclusions:

  • MEK inhibition represents a promising therapeutic avenue for refractory epilepsy in selected RASopathies.
  • Further clinical trials are warranted to explore the potential and limitations of MEK inhibitors in this patient population.